Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI
- PMID: 12756503
- DOI: 10.1007/s00259-003-1163-8
Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI
Abstract
The diagnostic value of technetium-99m tetrofosmin (TF) washout in hypertrophic cardiomyopathy (HCM) was examined by investigating its relation to the metabolic abnormality depicted by iodine-123 beta-methyl- p-iodophenylpentadecanoic acid (BMIPP) uptake and the left ventricular (LV) myocardial wall thickness as measured by magnetic resonance imaging (MRI). TF washout was evaluated in 31 patients with HCM and 23 normal control subjects using 30-min (early) and 3-h (delayed) TF single-photon emission tomography images. The LV myocardial wall was divided into 19 segments and the percentage TF washout, regional BMIPP uptake and LV wall thickness were measured in each segment. Mean TF washout in the patients with HCM was significantly faster than that in normal control subjects (23.7+/-5.7 vs 13.4+/-4.1, P<0.0001). In the patients with HCM, TF washout showed an excellent correlation with MRI wall thickness ( r=0.82, P<0.0001) and a good inverse correlation with regional BMIPP uptake ( r=-0.72, P<0.0001). In addition, a good linear correlation was observed between TF uptake and MRI wall thickness in the 19 regional segments. In conclusion, the degree of TF washout corresponds well with the severity of myocardial wall thickness and the degree of metabolic abnormality in patients with HCM. These results suggest that enhanced TF washout might provide additional clinical information regarding metabolic alterations in HCM.
Similar articles
-
Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cardiomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT.Ann Nucl Med. 2003 Oct;17(7):541-8. doi: 10.1007/BF03006666. Ann Nucl Med. 2003. PMID: 14651352 Clinical Trial.
-
Abnormal retention of 99mTc-TF in a hamster model of cardiomyopathy analyzed by 99mTc-TF and 125I-BMIPP autoradiography.Ann Nucl Med. 2004 May;18(3):195-202. doi: 10.1007/BF02985000. Ann Nucl Med. 2004. PMID: 15233280
-
Changes in cardiac sympathetic nerve innervation and activity in pathophysiologic transition from typical to end-stage hypertrophic cardiomyopathy.J Nucl Med. 2003 Oct;44(10):1612-7. J Nucl Med. 2003. PMID: 14530475 Clinical Trial.
-
Hypertrophic cardiomyopathy: functional aspects by tagged magnetic resonance imaging.Adv Exp Med Biol. 1995;382:293-301. doi: 10.1007/978-1-4615-1893-8_29. Adv Exp Med Biol. 1995. PMID: 8540406 Review.
-
Nuclear cardiac imaging in hypertrophic cardiomyopathy.J Nucl Cardiol. 2011 Feb;18(1):123-34. doi: 10.1007/s12350-010-9279-2. J Nucl Cardiol. 2011. PMID: 20737262 Review. No abstract available.
Cited by
-
Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.J Cardiovasc Transl Res. 2009 Dec;2(4):398-406. doi: 10.1007/s12265-009-9133-6. Epub 2009 Oct 16. J Cardiovasc Transl Res. 2009. PMID: 20559998 Review.
-
Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy.J Nucl Cardiol. 2010 Dec;17(6):1082-90. doi: 10.1007/s12350-010-9266-7. Epub 2010 Jul 16. J Nucl Cardiol. 2010. PMID: 20635229
-
Clinical Implications of the Washout Phenomenon in Technetium-99m (99mTc-) Labeled Compounds for Myocardial Perfusion Imaging.Ann Nucl Cardiol. 2024;10(1):55-58. doi: 10.17996/anc.24-00010. Epub 2024 Oct 31. Ann Nucl Cardiol. 2024. PMID: 39635330 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous